Evidence map›Paper›PMID 42070972›Full record

ArticleCancer science2026

Super-Enhancer Formation in Scirrhous Gastric CAFs, and the Presence of a Stromal Field in Non-Cancerous Tissues.

Yoshimi Yasukawa, Naoko Hattori, Yu-Yu Liu, Masayuki Tobo, Genki Yamagishi, Takahiro Irie, Shigeki Sekine, Tohru Kiyono, Satoshi Yamashita, Yukinori Yamagata and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yoshimi YasukawaDepartment of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan.
Naoko HattoriDepartment of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0901-4869
Yu-Yu LiuDepartment of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan.
Masayuki ToboLaboratory of Integrative Metabolic Regulation, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.
Genki YamagishiLaboratory of Integrative Metabolic Regulation, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.
Takahiro IrieDepartment of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan.
Shigeki SekineDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Tohru KiyonoProject for Prevention of HPV-Related Cancer, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chiba, Japan.ORCID https://orcid.org/0000-0003-1769-403X
Satoshi YamashitaDivision of Biotechnology, Graduate School of Engineering, Maebashi Institute of Technology, Maebashi, Gunma, Japan.ORCID https://orcid.org/0000-0002-8609-5797
Yukinori YamagataDivision of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Takaki YoshikawaDivision of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Yasuyuki SetoDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Toshikazu UshijimaDepartment of Epigenomics, Institute for Advanced Life Sciences, Hoshi University, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3405-7817

Funding

Japan Agency for Medical Research and Development 20jk0210009Japan Agency for Medical Research and Development JP22gm1310006Japan Society for the Promotion of Science JP20K07628Japan Society for the Promotion of Science JP20K16347Japan Society for the Promotion of Science JP21K20944
6 · The paper itself

Abstract

Scirrhous gastric cancer has aggressive clinical courses and is characterized by dominating cancer-associated fibroblasts (CAFs). However, the origin of scirrhous CAFs remains unclear, and we here aimed to explore the epigenetic basis for scirrhous CAFs and their origin. Conditioned medium (CM) from scirrhous CAFs was shown to have a marked effect (2-4 folds) on the migration of gastric cancer cells compared to that from non-scirrhous CAFs. The aggressive phenotype of scirrhous CAFs was associated with activation of TGFβ1 and NF-κB, along with increased expression of their downstream genes. Scirrhous CAFs had heavily acetylated super-enhancers, and therapeutic targeting of super-enhancers by a BET bromodomain inhibitor, mivebresib and JQ-1, markedly decreased their migration-promoting activity. Notably, in scirrhous gastric cancer patients, normal fibroblasts in non-cancerous tissues also had a strong migration-promoting effect. It was suggested that fibroblasts in the non-cancerous tissue of scirrhous gastric patients have already acquired tumor-promoting capacity, forming a stromal field for scirrhous gastric cancer although its spatial extent remains to be solved.

Indexed as

Adenocarcinoma, ScirrhousCancer-Associated FibroblastsStomach NeoplasmsSuper EnhancersAcetylationAzepinesBromodomain Containing ProteinsCell Line, TumorCell MovementEpigenesis, GeneticGene Expression Regulation, NeoplasticHeterocyclic Compounds, 4 or More RingsHumansNF-kappa BSulfoxidesTranscription FactorsAzepinesBromodomain Containing ProteinsGSK1210151AHeterocyclic Compounds, 4 or More Rings(+)-JQ1 compoundNF-kappa BSulfoxidesTranscription FactorsTransforming Growth Factor beta1TriazolesBET inhibitorenhancerepigeneticsepigenomegastric cancerhistone acetylation

Identifiers

PMID42070972
PMCPMC13327015

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.